Research programme: enzyme precursors - Propanc

Drug Profile

Research programme: enzyme precursors - Propanc

Alternative Names: PRP-DCM

Latest Information Update: 04 Apr 2017

Price : $50

At a glance

  • Originator Propanc Health Group Corporation
  • Class Enzyme precursors
  • Mechanism of Action PAR-2 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Colorectal cancer; Ovarian cancer; Pancreatic cancer; Solid tumours

Most Recent Events

  • 28 Mar 2017 Propanc files for patent protection under Patent Cooperation Treaty for enzyme precursors before March 2017
  • 04 Jan 2017 Propanc files for new patent protection for enzyme precursors in Australia, Spain and USA
  • 04 Jan 2017 Preclinical trials in Ovarian cancer in Australia (IV) before January 2017
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top